Inhalerx Ltd (IRX) - Total Assets
Based on the latest financial reports, Inhalerx Ltd (IRX) holds total assets worth AU$1.21 Million AUD (≈ $854.84K USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore IRX cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Inhalerx Ltd - Total Assets Trend (2016–2025)
This chart illustrates how Inhalerx Ltd's total assets have evolved over time, based on quarterly financial data. See Inhalerx Ltd (IRX) net assets for net asset value and shareholders' equity analysis.
Inhalerx Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Inhalerx Ltd's total assets of AU$1.21 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 36.2% |
| Accounts Receivable | AU$0.00 | 0.0% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$0.00 | 0.0% |
| Intangible Assets | AU$0.00 | 0.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Inhalerx Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Inhalerx Ltd (IRX) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Inhalerx Ltd's current assets represent 100.0% of total assets in 2025, an increase from 95.9% in 2016.
- Cash Position: Cash and equivalents constituted 36.2% of total assets in 2025, down from 88.8% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 3.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Inhalerx Ltd Competitors by Total Assets
Key competitors of Inhalerx Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Sk Biopharmaceuticals Co Ltd
KO:326030
|
Korea | ₩1.20 Trillion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $398.69 Million |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Theravance Biopharma Inc
F:0TB
|
Germany | €415.46 Million |
Inhalerx Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.58 | 0.92 | 3.27 |
| Quick Ratio | 0.58 | 0.92 | 3.20 |
| Cash Ratio | 0.00 | 0.00 | 2.96 |
| Working Capital | AU$-858.51K | AU$-63.65K | AU$1.32 Million |
Inhalerx Ltd - Advanced Valuation Insights
This section examines the relationship between Inhalerx Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.55 |
| Latest Market Cap to Assets Ratio | 3.46 |
| Asset Growth Rate (YoY) | 69.6% |
| Total Assets | AU$1.21 Million |
| Market Capitalization | $4.18 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Inhalerx Ltd's assets at a significant premium (3.46x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Inhalerx Ltd's assets grew by 69.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Inhalerx Ltd (2016–2025)
The table below shows the annual total assets of Inhalerx Ltd from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | AU$1.21 Million ≈ $854.84K |
+69.59% |
| 2024-12-31 | AU$712.40K ≈ $504.07K |
-54.82% |
| 2023-12-31 | AU$1.58 Million ≈ $1.12 Million |
-30.17% |
| 2022-12-31 | AU$2.26 Million ≈ $1.60 Million |
-22.96% |
| 2021-12-31 | AU$2.93 Million ≈ $2.07 Million |
+53.95% |
| 2020-12-31 | AU$1.90 Million ≈ $1.35 Million |
+205.27% |
| 2019-12-31 | AU$623.71K ≈ $441.32K |
-79.82% |
| 2018-12-31 | AU$3.09 Million ≈ $2.19 Million |
-39.23% |
| 2017-12-31 | AU$5.09 Million ≈ $3.60 Million |
-40.69% |
| 2016-12-31 | AU$8.58 Million ≈ $6.07 Million |
-- |
About Inhalerx Ltd
Nexalis Therapeutics Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. It is developing IRX-211 that has completed Phase 1 clinical trial for the treatment of Breakthrough Cancer Pain (BTcP); and IRX-616a that is in preclinical trial for panic disorder (PD). The company was formerly known as InhaleRx Limited and changed its name Nexali… Read more